MedTrace Logo

Point-of-Care Testing of Coagulation in Patients Treated With Direct Oral Anticoagulants Extended

NCT04679298 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2023-06-29

No results posted yet for this study

Summary

The investigators' study aims to test the correlation between CoaguChek point-of-care aPTT testing (Roche, Switzerland) and low plasma levels of all four currently EMA approved direct oral anticoagulants (DOAC; apixaban, dabigatran, edoxaban, and rivaroxaban) and to determine the diagnostic accuracy of POCT to rule out or detect relevant levels of DOAC in real-life stroke patients. Relevant levels are defined as current treatment thresholds according to international guidelines, i.e. 30 and 50 ng/mL.

Conditions

  • Anticoagulation With Direct Oral Anticoagulants

Sponsors & Collaborators

  • Heart and Diabetes Center North Rhine-Westphalia

    collaborator OTHER

  • University Hospital Tuebingen

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-01-05
Primary Completion
2022-09-28
Completion
2023-08-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04679298 on ClinicalTrials.gov